Current Pharmacology Reports
August 24, 2026
John I. Ogbu, Caroline V. L. Moreira, Ayobami J. Olusola et al.
Abstract Purpose of Review This review integrates evidence from the literature with network pharmacology tools to explore the decoction’s multitarget potential and provide multilevel insights into its therapeutic role in neuropsychiatric disorders. Recent Findings Neuropsychiatric disorders remain a significant health burden, underscoring the limitations of single-target pharmacotherapies and...
Fitoterapia
June 1, 2023
Caroline V. L. Moreira, Ana Luiza G Faria, Daiany P B Silva et al.
2 citations
Previous studies have attributed the prominent analgesic, hallucinogenic, sedative, and anxiolytic properties of Salvia divinorum to Salvinorin A. However, the overall pharmacological profile of this isolate limits its clinical applications. To address these limitations, our study evaluates the C(22)-fused-heteroaromatic analogue of salvinorin A [2-O-salvinorin B benzofuran-2-carboxylate]...
Journal of Psychopharmacology
July 2019
Adam W Keasling, Pankaj Pandey, Robert J Doerksen et al.
Salvinorin A is known as a highly selective kappa opioid receptor agonist with antinociceptive but mostly pro-depressive effects. In this article, we present its new semisynthetic analog with preferential mu opioid affinity, and promising antinociceptive, as well as antidepressant-like activities. Competitive binding studies were performed for salvindolin with kappa opioid and mu opioid. The...
Frontiers in Psychiatry
2019
Jordan K Zjawiony, Antônio S Machado, Ricardo Menegatti et al.
18 citations
Over the years, pain has contributed to low life quality, poor health, and economic loss. Opioids are very effective analgesic drugs for treating mild, moderate, or severe pain. Therapeutic application of opioids has been limited by short and long-term side effects. These side effects and opioid-overuse crisis has intensified interest in the search for new molecular targets and drugs. The...